ArriVent Biopharma has discovered first-of-its-kind furmonertinib for the treatment of specific type of lung cancer, namely non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Furmonertinib is a novel, orally administered drug designed to inhibit the activity of the epidermal growth factor receptor (EGFR) kinase. It is specifically engineered to have a high ability to penetrate the blood-brain barrier, making it potentially effective in treating brain metastases from lung cancer.
Furmonertinib is developed to target a wide range of EGFR mutations, including classical mutations like exon 19 deletions and L858R, as well as uncommon mutations such as exon 20 insertions. EGFR mutations play a critical role in the development and progression of NSCLC.
Interim results from clinical trials have shown that furmonertinib has demonstrated promising anti-tumour activity when used as a single agent. This suggests that it may be an effective treatment option for NSCLC patients, both in the first-line setting and for those who have been previously treated.
Lung cancer is a significant global health concern and is the leading cause of cancer-related deaths for both men and women worldwide. NSCLC is the common type of lung cancer, affecting approximately 85 percent of all cases.
The breakthrough therapy designation granted by the U.S. Food and Drug Administration (FDA) for furmonertinib in the treatment of previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) is a significant regulatory milestone.